Invasive Breast Carcinoma
Breast Cancer Drug Wins Approval Despite Rejection by Agency Advisors
The FDA granted accelerated approval to camizestrant (Etcamah) combined with a CDK4/6 inhibitor in adults with HR-positive, HER2-negative advanced breast cancer in whom an ESR1 mutation is detected in ctDNA during aromatase inhibitor plus CDK4/6 inhibitor therapy. The basis is the phase 3 SERENA-6 t…
Read the full story →Phase 3 trial: neoadjuvant anbenitamab with albumin-bound docetaxel raised pathological complete response in HER2-positive breast cancer to 62.4%
In a phase 3 randomized trial in 521 patients with stage II-III HER2-positive breast cancer, neoadjuvant anbenitamab (a biparatopic HER2 antibody) with albumin-bound docetaxel achieved a total pathological complete response in 62.4% of patients (164/263) versus 51.2% (132/258) with standard trastuzu…
Read the full story →Induced proximity comes of age
The May 2026 approval of vepdegestrant — restricted to ESR1-mutated, ER-positive, HER2-negative advanced breast cancer — made the first PROTAC degrader a clinical reality and validated induced proximity as a pharmacological modality: drugs that bring a target protein together with the cell's degrada…
Read the full story →Global cancer statistics 2024: translating epidemiological trends into priorities for healthcare systems
A review in Nature Reviews Clinical Oncology discusses the global cancer burden using GLOBOCAN 2024 estimates: in 2024, 20.6 million people across 186 countries were diagnosed with cancer and 9.8 million died of it. Lung cancer remains the most common — 2.6 million new cases (12.8%) and 1.9 million …
Read the full story →Vepdegestrant, the first-in-class PROTAC degrader, approved for ESR1-mutated advanced breast cancer
On 1 May 2026 the FDA approved vepdegestrant (Veppanu), the first PROTAC protein degrader to reach clinical use, exclusively for ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer that has progressed after at least one line of endocrine therapy. In the registrational VERIT…
Read the full story →Gedatolisib in HR+/HER2− PIK3CA wild-type breast cancer: median PFS 9.3 vs 2.0 months in phase 3
In the phase 3 VIKTORIA-1 trial (n=392), the triplet of gedatolisib, palbociclib and fulvestrant extended median progression-free survival to 9.3 months versus 2.0 months with fulvestrant alone (HR 0.24; 95% CI 0.17-0.35) in HR+/HER2− advanced breast cancer without a PIK3CA mutation, after progressi…
Read the full story →Datopotamab deruxtecan extends overall survival in first-line metastatic TNBC when immunotherapy is not an option: 23.7 versus 18.7 months (TROPION-Breast02)
In the phase 3 TROPION-Breast02 trial, datopotamab deruxtecan — a TROP2-directed antibody-drug conjugate — extended median overall survival to 23.7 months versus 18.7 months with the investigator's choice of chemotherapy (HR 0.79; 95% CI 0.64-0.98; p=0.0291), with median progression-free survival of…
Read the full story →